World Health Organization Raises Alert Over Critical Scarcity of Obesity Medications

Under one in 10 patients eligible to benefit from weight-loss injections including Wegovy have access to them, states the WHO as it releases its inaugural guidance on the therapies.

Considering over a billion people worldwide now obese, it is urging increased and just access to these injectable treatments.

According to estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.

"The new guidance recognises that obesity is a lifelong illness that can be managed with thorough and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are major barriers to widespread availability to the treatments that can assist patients in reducing significant body mass, says the agency.

Weight-Loss Drug Scarcity

Even in the present best projected outlook, the manufacturing of these medications might only reach about 100 million people – under 10% of the global need, as stated by the health organization.

The recommendation calls on governments and firms to widen availability, through measures like patent sharing.

The intellectual property rights on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026.

The Way Obesity Jabs Operate

These medications replicate a natural hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so users consume fewer calories.

Patients commonly begin shedding pounds within a few weeks of beginning the once-weekly jabs.

Research suggests patients may see weight return within a year of halting the medication, as their normal appetite resume.

Being carrying excess weight raises your chance for experiencing medical conditions, including diabetes, cardiovascular issues, brain attack, and certain cancers.

Excess weight concerns people in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the WHO.